|ATC code||N05CD12 (WHO)|
|Biological half-life||3-4 hours|
|UNII||verifiedrevid = 457288969 231RV72C8L verifiedrevid = 457288969|
|Chemical and physical data|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Doxefazepam (marketed under brand name Doxans) is a benzodiazepine derivative drug developed by Schiapparelli in the 1970s. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is used therapeutically as a hypnotic. According to Babbini and colleagues in 1975, this derivative of flurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals. Section 5.5 of the article Doxefazepam in volume 66 of the World Health Organization's (WHO) and International Agency for Research on Cancer's (IARC) IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans, an article describing the carcinogenic/toxic effects of doxefazepam on humans and experimental animals, states that there is "inadequate evidence in humans for the carcinogenicity of doxefazepam" and limited evidence in experimental for the carcinogenicity of doxefazepam," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."
- DE Patent 2338058 - BENZODIAZEPINVERBINDUNGEN FUER DIE THERAPIE
- Rodriguez, G; Rosadini, G; Sannita, WG; Strumia, E (1984). "Effects of doxefazepam on normal sleep. An EEG and neuropsychological study". Neuropsychobiology. 11 (2): 133–9. doi:10.1159/000118066. PMID 6483162.
- Babbini M, Torrielli MV, Strumia E, Gaiardi M, Bartoletti M, De Marchi F (August 1975). "Sedative-hypnotic properties of a new benzodiazepine in comparison with flurazepam. Pharmacological and clinical findings". Arzneimittel-Forschung. 25 (8): 1294–1300. PMID 241364.
- "Doxefazepam" (PDF). IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans. International Agency For Research On Cancer (IARC). 66: 97–104. 13–20 Feb 1996. Retrieved 10 July 2014.